Patents Examined by Anne M. Gussow
  • Methods and compositions for modulating tumor cell activity
    Patent number: 8044179
    Abstract: Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: October 25, 2011
    Inventors: Maureen D. O'Connor-McCourt, Christiane Cantin, Anne E. G. Lenferink
  • Alpha 5-beta 1 antibodies and their uses
    Patent number: 8039596
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: October 18, 2011
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Steven Lee Bender, Gerald Fries Casperson, Dana Dan Hu-Lowe, Xin Jiang, Gang Li, Michael Aidan North, Jianying Wang, Grant Wickman, Peter Brams, Haichun Huang, Brigitte Devaux, Haibin Chen, Dawn M. Tanamachi, Kristopher Toy, Lan Yang, Tim W. Sproul, Mark Yamanaka
  • Antibodies and related molecules that bind to 24P4C12 proteins
    Patent number: 8039597
    Abstract: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 18, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Steven B. Kanner, Pia M. Challita-Eid, Xiao-chi Jia, Jean Gudas, Aya Jakobovits
  • Degraded TPO agonist antibody
    Patent number: 8034903
    Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: October 11, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
  • Cell free screening assay and methods of use
    Patent number: 8030004
    Abstract: Methods are disclosed for identifying agents for the treatment of cancer and/or Fanconi anemia using Xenopus egg cell free extracts from which the endogenous DNA has been removed. The assays and method described herein are easily adaptable to high throughput techniques for example to screen large numbers of agents as possible agents for the treatment of cancer and/or Fanconi anemia. Kits for carrying out the disclosed assays and methods also are disclosed. Agents identified by these methods are also disclosed as are methods for treating a subject with cancer and/or Fanconi anemia with these agents.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: October 4, 2011
    Assignee: Oregon Health & Science University
    Inventors: Maureen Hoatlin, Stacie Stone, Alexandra Sobeck, Vincenzo Costanzo, Jean Gautier, Igor Landais
  • Anti-CD26 antibodies and methods of use thereof
    Patent number: 8030469
    Abstract: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides, such as to inhibit cell proliferation and in the treatment of conditions associated with CD26, are also provided.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 4, 2011
    Assignee: SBI Incubation Co., Ltd.
    Inventors: Teikichi Aoyagi, Peter Peizhi Luo, Pingyu Zhong, Mark Hsieh, Yan Li, Kevin Caili Wang, Chikao Morimoto
  • Compositions and methods for binding sphingosine-1-phosphate
    Patent number: 8026342
    Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate
    Patent number: 8025877
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Williams
  • 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
    Patent number: 8013126
    Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: September 6, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Daniel E. H. Afar, Pia M. Challita-Eid, Elana Levin, Steve Chappell Mitchell, Rene S. Hubert
  • Methods of treating cancer using immunostimulatory oligonucleotides
    Patent number: 8008266
    Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: August 30, 2011
    Assignees: University of Iowa Foundation, The United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
    Inventors: Arthur M. Krieg, Alfred D. Steinberg, Dennis Klinman
  • Means and methods for the treatment of tumorous diseases
    Patent number: 8007796
    Abstract: The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: August 30, 2011
    Assignee: Micromet AG
    Inventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo
  • Combination therapy for treatment of cancer
    Patent number: 8008256
    Abstract: The invention relates to compositions and methods for treating diseases. In particular aspects, the invention relates to administering a combination of a disintegrin with a microtubule stabilizing agent useful for treatment of cancer.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: August 30, 2011
    Assignee: University of Southern California
    Inventors: Francis S Markland, Jr., Steven Swenson, Jacek Pinski
  • Detection of CXADR protein for diagnosis of kidney cancer
    Patent number: 7998689
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: August 16, 2011
    Assignee: Celera Corporation
    Inventors: Elizabeth Joseloff, Steve Ruben, Tao He, Yeounjin Kim
  • Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
    Patent number: 7999071
    Abstract: Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 16, 2011
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Effector function enhanced recombinant antibody composition
    Patent number: 7994290
    Abstract: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: August 9, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7989595
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: August 2, 2011
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, William Mallet, Paul Polakis
  • SSX-2 peptides presented by HLA class II molecules
    Patent number: 7989587
    Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: August 2, 2011
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Maha Ayyoub, Danila Valmori
  • Compositions and methods for the therapy and diagnosis of cytomegalovirus
    Patent number: 7982012
    Abstract: The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: July 19, 2011
    Assignee: Theraclone Sciences, Inc.
    Inventor: Ole Olsen
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 7982017
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 19, 2011
    Assignee: BioAlliance C.V.
    Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
  • Anti-inflammatory dAb
    Patent number: 7981414
    Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: July 19, 2011
    Assignee: Cephalon Australia Pty Ltd
    Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings